Red Clover for Menopause and Hot Flashes

Red clover extract capsules beside the fresh flowers
Red clover extract capsules beside the fresh flowers

Hot flashes are the reason most people buy red clover, and they are also the reason red clover is one of the most argued-about herbs in the supplement aisle. The claim is straightforward and appealing: menopause brings a fall in the body's own estrogen, red clover contains weak plant estrogens, therefore red clover should soften the symptoms. The trials that tested that claim have been running since the late 1990s, and after a quarter-century of them the field has still not agreed on an answer.

This page does not resolve the disagreement, because the evidence does not resolve it. What it does is lay the record out honestly — the trials that reported a benefit, the trials that reported nothing, what the pooled reviews concluded, and the several good reasons why studies of the same herb keep landing in different places. The fair one-sentence summary, and the one this page will keep returning to, is that red clover's effect on hot flashes is contested, and the better-controlled evidence is largely null.


Table of Contents

  1. What a Hot Flash Actually Is
  2. Why a Plant Estrogen Was Expected to Help
  3. The Trials That Found a Benefit
  4. The Trials That Found Nothing
  5. What the Pooled Reviews Concluded
  6. The Placebo Problem
  7. Why the Trials Disagree
  8. Fermented Extracts and the Equol Question
  9. Symptoms Other Than Hot Flashes
  10. Doses, Products and a Fair Trial
  11. How Red Clover Sits Beside the Alternatives
  12. The Honest Verdict
  13. Key Research Papers
  14. Safety and Disclaimer
  15. Connections
  16. Featured Videos

What a Hot Flash Actually Is

A hot flash — clinicians call the group of them vasomotor symptoms — is a sudden, involuntary surge of heat, usually starting in the chest, neck and face, often with flushing, sweating, a racing heart and then a chill as the sweat evaporates. It typically lasts one to five minutes. At night the same event becomes a night sweat, and the sleep it destroys is frequently the part that wears people down most.

The underlying mechanism is not simply "low estrogen." The current understanding centres on the brain's thermoregulatory centre in the hypothalamus, where a narrowed thermoneutral zone means that a trivial rise in core temperature that would once have gone unnoticed now trips a full heat-dumping response — skin vessels dilate, sweat glands fire. Falling and fluctuating estrogen is what narrows that zone, acting partly through a population of hypothalamic neurons involved in temperature control. This matters for red clover because it clarifies what a phytoestrogen would have to do to help: not simply exist in the bloodstream, but exert enough estrogenic signalling in the brain to widen the thermoneutral zone again. That is a considerable amount to ask of a compound hundreds of times weaker than estradiol.

Vasomotor symptoms are also not a brief nuisance for most people. Long-term cohort research has found that the median duration of frequent hot flashes runs to several years, with a substantial minority experiencing them for a decade or more. Any remedy therefore has to be judged over months, not days.

Why a Plant Estrogen Was Expected to Help

Red clover's four isoflavones are biochanin A, formononetin, genistein and daidzein. Biochanin A and formononetin dominate the dried flowering tops; digestion demethylates them into genistein and daidzein respectively, and those two are the more receptor-active pair. All four are phytoestrogens: molecules shaped closely enough like estradiol to occupy an estrogen receptor and produce a faint version of the estrogen signal.

Two features of that signal shaped expectations. First, isoflavones bind preferentially to estrogen receptor beta rather than estrogen receptor alpha, which raised the hope of a naturally tissue-selective effect — helpful where ER-beta predominates, quiet elsewhere. Second, their potency at the receptor is a small fraction of estradiol's, which suggested a favourable safety profile. The chemistry and receptor behaviour are set out in Phytoestrogens derived from red clover: an alternative to estrogen replacement therapy? (The Journal of Steroid Biochemistry and Molecular Biology, 2005) — PubMed PMID: 15876415. Evidence tier: laboratory pharmacology.

The rationale was never unreasonable. It simply turned out that a plausible mechanism and a measurable clinical benefit are two different things, and red clover is a textbook illustration of the gap between them.

The Trials That Found a Benefit

Some randomized, placebo-controlled trials did report that red clover reduced hot flashes. These deserve to be stated plainly rather than waved away.

The most-cited is Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo (Maturitas, 2002), which tested a standardized extract delivering 80 mg of isoflavones per day and found a significant reduction in flush frequency against placebo — PubMed PMID: 12161042. This single trial did a great deal to establish red clover's commercial reputation, and the 80 mg dose it used has been the benchmark ever since. Evidence tier: randomized clinical trial.

Other trials produced favourable or partially favourable results. The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: a randomized, double-blind, placebo-controlled study (Gynecological Endocrinology, 2005) reported improvement in menopausal symptom scores — PubMed PMID: 16373244. And the fermented-extract trial discussed further down, Combined Red Clover isoflavones and probiotics potently reduce menopausal vasomotor symptoms (PLoS ONE, 2017), reported one of the largest effects in the whole literature — PubMed PMID: 28591133. Evidence tier: randomized clinical trials, individually small.

A newer trial points the same way. Isoflavones obtained from red clover improve both dyslipidemia and menopausal symptoms in menopausal women: a prospective randomized placebo-controlled trial (Climacteric, 2024) gave 75 postmenopausal women with high blood fats (dyslipidemia) either 40 mg of red clover isoflavones twice daily (39 women) or a starch placebo capsule twice daily (36 women) for 6 months. In the red clover group, scores on the Menopause Rating Scale (an overall menopause symptom score) fell significantly at both 3 and 6 months; total cholesterol, LDL cholesterol and triglycerides fell, and HDL cholesterol rose. Apart from LDL cholesterol and the urogenital part of the symptom score at 3 months, the improvements were significantly in favour of red clover — PubMed PMID: 39254422. Evidence tier: randomized clinical trial.

What these positive results share is a pattern worth noting: they tend to be smaller, several used commercially sponsored or commercially developed products, and their effect sizes vary widely. None of that makes them wrong. It does mean they cannot carry the argument alone.

The Trials That Found Nothing

Set against those results is a set of trials, generally larger and more independently funded, that found red clover no better than a dummy pill.

The most important is the ICE Study — Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study — a randomized controlled trial (JAMA, 2003). It tested two different red clover isoflavone products against placebo in women with frequent hot flashes and found that neither product reduced flashes significantly more than placebo — PubMed PMID: 12851275. The trial enrolled 252 women who were having about 8 hot flashes a day (8.1 on average). After 12 weeks, daily hot flashes had fallen by 5.1 with the 82 mg-a-day product, 5.4 with the 57 mg-a-day product and 5.0 with placebo. Women on the 82 mg product saw their flashes fall faster than the placebo group (41%, P = .03), but the authors concluded that “neither supplement had a clinically important effect” on hot flashes or other symptoms of menopause. Testing two products at once was a deliberate strength: it made "you tested the wrong extract" much harder to argue. Evidence tier: randomized clinical trial, negative.

A second important negative is Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial (Menopause, 2009), which compared both botanicals against placebo in the same trial and found neither outperformed it — PubMed PMID: 19609225. After 12 months, the number of vasomotor symptoms (hot flashes and night sweats) had fallen by 57% with red clover, 34% with black cohosh, 63% with placebo and 94% with estrogen-plus-progestin hormone therapy; only hormone therapy differed significantly from placebo. Safety monitoring found both standardized botanical extracts “safe as administered” over the 12 months of daily use. Evidence tier: randomized clinical trial, negative.

Earlier work pointed the same way. The effect of Promensil, an isoflavone extract, on menopausal symptoms (Climacteric, 1999) and the companion Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women (Climacteric, 1999) both failed to demonstrate a clear advantage over placebo — PubMed PMID: 11910671 and PubMed PMID: 11910672. Notably, the first of those tested the same standardized red clover extract as the positive 2002 Maturitas trial. Evidence tier: randomized clinical trials, negative.

What the Pooled Reviews Concluded

When individual trials conflict, the usual next step is to pool them. Red clover has been pooled repeatedly, and the pooled results are themselves not unanimous — though they trend clearly toward caution.

The most independent and most authoritative is the Cochrane review Phytoestrogens for menopausal vasomotor symptoms (Cochrane Database of Systematic Reviews, 2013). Cochrane reviews are produced by an international non-profit with strict conflict-of-interest rules, which is precisely why their verdict carries weight. It included 43 randomized trials with 4,364 women. Most of those trials were too different from one another to combine; the five trials of one standardized red clover extract were pooled and showed no significant difference in daily hot flashes against placebo (mean difference −0.93 flashes a day, 95% CI −1.95 to 0.10). Four trials that could not be pooled suggested that extracts high in genistein (more than 30 mg a day) consistently reduced how often hot flashes came. The authors concluded there was no conclusive evidence that phytoestrogen supplements reduce the frequency or severity of hot flashes and night sweats — PubMed PMID: 24323914. Evidence tier: systematic review of randomized trials.

Trifolium pratense isoflavones in the treatment of menopausal hot flushes: a systematic review and meta-analysis (Phytomedicine, 2007) pooled the red-clover-specific trials and found at most a small reduction in flush frequency — PubMed PMID: 17239573. Five trials (40–82 mg a day) were pooled: women on red clover had about 1.5 fewer hot flashes a day than those on placebo (p = 0.05), which the authors called “marginally significant”, adding that whether an effect of that size is clinically relevant is unclear.

The most favourable pooled analysis narrowed the field deliberately: Effects of a standardised extract of Trifolium pratense (Promensil) at a dosage of 80 mg in the treatment of menopausal hot flushes: a systematic review and meta-analysis (Phytomedicine, 2017) restricted itself to trials of one standardized extract at one dose. Pooling three studies, it found 3.63 fewer hot flashes a day than placebo (95% CI 2.70 to 4.56), which the authors called a statistical and clinically relevant reduction; they also reported a substantive difference between the results of cross-over and parallel-arm trial designs — PubMed PMID: 28160855. That restriction is both its strength and its weakness. It arguably compares like with like; it also, by design, excludes trials that used other products and reported nothing.

Later pooled work has continued in the same vein. Red clover for treatment of hot flashes and menopausal symptoms: a systematic review and meta-analysis (Journal of Obstetrics and Gynaecology, 2016) reported about 2 fewer hot flashes a day with red clover than in the control groups (mean difference −1.99), a result that fell just short of statistical significance (p = 0.067), and suggested the effect may be larger in women with 5 or more hot flashes a day — PubMed PMID: 26471215 — and Evaluation of Clinical Meaningfulness of Red Clover (Trifolium pratense L.) Extract to Relieve Hot Flushes and Menopausal Symptoms in Peri- and Post-Menopausal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (Nutrients, 2021) asked the sharper question its title implies — not whether an effect can be detected, but whether it is large enough for a woman to notice — PubMed PMID: 33920485. Pooling eight trials, it found 1.73 fewer hot flashes a day with red clover than with placebo (95% CI −3.28 to −0.18), with larger differences in postmenopausal women having 5 or more hot flashes a day, when follow-up was 12 weeks, at doses of 80 mg a day or more, and with formulas richer in biochanin A. That distinction — statistical detectability versus clinical meaningfulness — is the crux of the entire red clover debate.

The newest pooled analysis, The effectiveness of red clover on hot-flash in menopausal women: a GRADE-assessed systematic review and meta-analysis (European Journal of Obstetrics & Gynecology and Reproductive Biology, 2026), combined nine randomized placebo-controlled trials in women aged 40 to 65 who had 2.1 to 11.7 hot flashes a day, at doses of 37.1 to 160 mg of isoflavones daily for 12 weeks to 12 months. It found a statistically significant reduction in hot-flash frequency with red clover (standardized mean difference −0.446, 95% CI −0.807 to −0.084), which the authors describe as a small-to-moderate, “modest” effect; most of the trials had a low risk of bias — PubMed PMID: 42269521. Evidence tier: systematic review of randomized trials.

The Placebo Problem

Hot flashes are notoriously placebo-responsive. Across the 43 trials of the 2013 Cochrane review, hot-flash frequency in the placebo groups fell by anywhere from 1% to 59%, and the review noted a strong placebo effect in most trials. In the 2002 Maturitas trial, every woman first took placebo tablets for four weeks without knowing it, and hot-flash frequency fell by 16% before anyone received the extract. Several factors compound: symptoms fluctuate naturally and people enrol when they are at their worst, so regression to the mean flatters any treatment; keeping a daily symptom diary appears to change how symptoms are perceived; and expectation itself has genuine physiological effects on thermoregulation.

The practical consequence is severe. If placebo delivers a 40 percent reduction, an active treatment must produce a substantially larger reduction before the difference becomes statistically visible in a trial of realistic size. Many red clover trials enrolled fewer than a hundred women per arm, which is simply not enough power to detect a small true effect against a large placebo response. This means the null trials do not prove red clover does nothing. They prove that if it does something, that something is small — small enough to be hard to distinguish from a sugar pill under controlled conditions.

It also means that a reader who tries red clover and feels better has not proved it works either. Feeling better is exactly what a large fraction of the placebo groups did.

Why the Trials Disagree

Several concrete differences plausibly explain the split in results, and none of them is merely a technicality.

  1. Dose. Most trials have used roughly 40 mg to 80 mg of isoflavones daily; the nine trials in the 2026 pooled analysis ranged from 37.1 mg to 160 mg. The clearest positive signals cluster at 80 mg, and the 2017 meta-analysis restricted to that dose was the most favourable pooled result. A genuine dose threshold is a real possibility.
  2. Extract and formulation. "Red clover" on a label can mean a standardized isoflavone extract, a fermented extract, a powdered flower capsule or a tea. These are not interchangeable, and their isoflavone content and bioavailability differ enormously.
  3. Raw-material variability. The plant itself is inconsistent. Seasonal variation of red clover (Trifolium pratense L., Fabaceae) isoflavones and estrogenic activity (Journal of Agricultural and Food Chemistry, 2006) documented how much isoflavone content and measured estrogenic activity shift with season and plant material — PubMed PMID: 16478248. Evidence tier: analytical chemistry.
  4. Baseline symptom severity. Trials enrolling women with very frequent flashes have more room to show improvement than those enrolling mild cases — but also a larger placebo response.
  5. Trial duration. Twelve weeks is the common length; some ran shorter. If the herb works slowly, short trials will miss it.
  6. The reader's own gut bacteria. The most interesting explanation, covered next.

Fermented Extracts and the Equol Question

Daidzein — the metabolite of red clover's formononetin — can be converted by certain intestinal bacteria into equol, a compound with notably stronger estrogen-receptor activity than daidzein itself. Crucially, only a minority of people carry the bacteria to do this. Estimates vary, but roughly a quarter to a half of Western adults are equol producers, with higher proportions reported in some East Asian populations. The chemistry and history are laid out in Equol: history, chemistry, and formation (The Journal of Nutrition, 2010) — PubMed PMID: 20519412. Evidence tier: human metabolism research.

If equol is what actually matters, then a trial that enrolled a random sample of women was, in effect, giving an active drug to a minority and an inert one to everyone else — and diluting any true effect toward zero. That is a genuinely plausible reason for a field full of borderline results.

A related idea lies behind fermented red clover extracts. In the one trial of such a product, probiotic lactic acid bacteria were added to the extract to ferment it, turning the isoflavones from their sugar-bound form (glycosides) into the free form (aglycones), which is meant to make them easier to absorb. That is a different step from turning daidzein into equol, and the trial did not measure equol. Combined Red Clover isoflavones and probiotics potently reduce menopausal vasomotor symptoms (PLoS ONE, 2017) gave 62 women either this preparation (34 mg of isoflavones a day, with probiotics) or a placebo for 12 weeks. Hot flashes counted by a skin-conductance monitor worn for 24 hours fell by 4.3 a day on the extract and rose by 0.79 a day on placebo — PubMed PMID: 28591133. Evidence tier: randomized clinical trial, single and small.

Honesty requires two qualifications. First, this is one small trial from one research group; it has not been independently replicated at scale, and a large early effect that shrinks on replication is one of the most common patterns in clinical research. Second, the fermented products used in that research are not what most bottles on a shelf contain. The equol hypothesis is the most interesting open question about red clover — it is not yet an answer.

Symptoms Other Than Hot Flashes

Menopause is not only vasomotor symptoms, and trials have looked at the rest with mostly weaker results.

Doses, Products and a Fair Trial

The trials above share several features that bear on how any one person’s experience with red clover compares with the research.

How Red Clover Sits Beside the Alternatives

Context helps, because red clover is rarely the only thing under consideration.

Hormone therapy remains by a wide margin the most effective treatment for vasomotor symptoms, typically reducing flash frequency by around three-quarters — a different order of magnitude from anything red clover has shown. It carries risks that require individual assessment; those are covered on Menopause & hormone replacement therapy (HRT) and hormone replacement therapy Risks. Red clover is not a substitute for it when symptoms are severe, and presenting it as one does readers a disservice.

Non-hormonal prescription options — including certain antidepressants, gabapentin and the newer neurokinin-3 receptor antagonists — have randomized evidence considerably stronger than red clover's; see Non-Hormonal Options.

Other botanicals. Black cohosh is the closest comparator and its evidence base is similarly contested — the 2009 Menopause trial found neither it nor red clover beat placebo. Sage has a smaller but not uninteresting literature for sweating specifically. Chasteberry is primarily a premenstrual rather than menopausal herb. None of these has evidence approaching that of the prescription options.

Non-pharmacological measures — layered clothing, keeping the bedroom cool, identifying personal triggers such as alcohol or hot drinks, weight management, and cognitive behavioural therapy for hot flashes, which has genuinely encouraging trial evidence for reducing how much flashes bother people — cost nothing and interact with nothing.

The Honest Verdict

Red clover for hot flashes is contested, and the better-controlled evidence is largely null. The largest and most independent trials found no advantage over placebo. The Cochrane review found no conclusive evidence of benefit. The pooled analyses that did find an effect mostly found a small one, and the most favourable of them restricted itself to a single product at a single dose.

Against that, red clover is generally well tolerated in the short term, some trials did report benefit, and the equol hypothesis offers a coherent reason why the herb might work for a subset of people while failing to show up in group averages. That is not nothing — but it is a hypothesis, not a demonstrated result.

In sum: for mild symptoms, the research points to a small effect at most, alongside good short-term tolerability in trials. In the one trial here that tested both against placebo, hormone therapy reduced vasomotor symptoms by 94% and red clover by 57%, against 63% on placebo. On the current evidence, the research does not establish that red clover “works” for hot flashes.

Key Research Papers

  1. Lethaby A, Marjoribanks J, Kronenberg F, et al. (2013). Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database of Systematic Reviews — PubMed PMID: 24323914
  2. Tice JA, Ettinger B, Ensrud K, et al. (2003). Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA — PubMed PMID: 12851275
  3. van de Weijer PH, Barentsen R. (2002). Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo. Maturitas — PubMed PMID: 12161042
  4. Coon JT, Pittler MH, Ernst E. (2007). Trifolium pratense isoflavones in the treatment of menopausal hot flushes: a systematic review and meta-analysis. Phytomedicine — PubMed PMID: 17239573
  5. Myers SP, Vigar V. (2017). Effects of a standardised extract of Trifolium pratense (Promensil) at a dosage of 80mg in the treatment of menopausal hot flushes: A systematic review and meta-analysis. Phytomedicine — PubMed PMID: 28160855
  6. Geller SE, Shulman LP, van Breemen RB, et al. (2009). Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause — PubMed PMID: 19609225
  7. Knight DC, Howes JB, Eden JA. (1999). The effect of Promensil, an isoflavone extract, on menopausal symptoms. Climacteric — PubMed PMID: 11910671
  8. Baber RJ, Templeman C, Morton T, et al. (1999). Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric — PubMed PMID: 11910672
  9. Booth NL, Piersen CE, Banuvar S, et al. (2006). Clinical studies of red clover (Trifolium pratense) dietary supplements in menopause: a literature review. Menopause — PubMed PMID: 16645539
  10. Hidalgo LA, Chedraui PA, Morocho N, et al. (2005). The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: a randomized, double-blind, placebo-controlled study. Gynecological Endocrinology — PubMed PMID: 16373244
  11. Lambert MNT, Thorup AC, Hansen ESS, et al. (2017). Combined Red Clover isoflavones and probiotics potently reduce menopausal vasomotor symptoms. PLoS ONE — PubMed PMID: 28591133
  12. Yigit E, Unsal S. (2024). Isoflavones obtained from red clover improve both dyslipidemia and menopausal symptoms in menopausal women: a prospective randomized placebo-controlled trial. Climacteric — PubMed PMID: 39254422
  13. Ghazanfarpour M, Sadeghi R, Roudsari RL, et al. (2016). Red clover for treatment of hot flashes and menopausal symptoms: A systematic review and meta-analysis. Journal of Obstetrics and Gynaecology — PubMed PMID: 26471215
  14. Kanadys W, Barańska A, Błaszczuk A, et al. (2021). Evaluation of Clinical Meaningfulness of Red Clover (Trifolium pratense L.) Extract to Relieve Hot Flushes and Menopausal Symptoms in Peri- and Post-Menopausal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients — PubMed PMID: 33920485
  15. Jiang W, Wu K. (2026). The effectiveness of red clover on hot-flash in menopausal women: a GRADE-assessed systematic review and meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology — PubMed PMID: 42269521
  16. Beck V, Rohr U, Jungbauer A. (2005). Phytoestrogens derived from red clover: an alternative to estrogen replacement therapy? The Journal of Steroid Biochemistry and Molecular Biology — PubMed PMID: 15876415
  17. Booth NL, Overk CR, Yao P, et al. (2006). Seasonal variation of red clover (Trifolium pratense L., Fabaceae) isoflavones and estrogenic activity. Journal of Agricultural and Food Chemistry — PubMed PMID: 16478248
  18. Setchell KD, Clerici C. (2010). Equol: history, chemistry, and formation. The Journal of Nutrition — PubMed PMID: 20519412

PubMed Topic Searches

  1. PubMed: Trifolium pratense randomized controlled trial menopause

Back to Table of Contents

Back to Table of Contents

Safety and Disclaimer

Red clover is a phytoestrogen, and its safety questions follow from that. Its isoflavones act on estrogen receptors. In the 12-month 2009 trial, standardized red clover was “safe as administered” in menopausal women. The concerns set out on the safety page are these. In pregnancy and breastfeeding there is no human safety data, and isoflavones can pass into breast milk. For a history of breast, uterine or ovarian cancer, endometriosis or uterine fibroids, the concern is that an added estrogen-like signal adds to what drives these conditions. With tamoxifen, a mouse study found that dietary genistein cancelled the drug’s tumour-suppressing effect (not shown in humans), and laboratory work raises a related concern for aromatase inhibitors. Red clover is listed among herbs that may add to the bleeding effect of warfarin, seen as a rise in the INR blood test, with the same theoretical concern for other anticoagulants and antiplatelet drugs. Hormone therapy and birth-control pills may interact with it, in a direction that is unclear. Conventional practice is to stop herbs with a bleeding concern about two weeks before scheduled surgery. The full picture, including the laboratory evidence behind each caution, is on Red Clover Isoflavones, Hormones and Safety. This page is educational information and not medical advice.

Connections

Back to Table of Contents